Automating Cell and Gene Therapy Manufacturing for Scale

Automating Cell and Gene Therapy Manufacturing for Scale

Cell and gene therapies (CGTs) have demonstrated transformative clinical potential, but manufacturing remains a major barrier to broader patient access. Highly manual, labor-intensive production processes limit throughput, introduce variability, and drive up costs, making it difficult to scale these therapies to meet growing demand. As the industry looks to expand access, there is increasing focus on how automation, robotics, and digitalization can enable more consistent, efficient, and scalable manufacturing without compromising the underlying biology.

In this episode of Off Script, we spoke with Edwin Stone, PhD, CEO of Cellular Origins, about the core bottlenecks constraining CGT manufacturing and how automation is beginning to address them. The conversation explores why labor remains a dominant cost driver, how process variability extends beyond patient starting material into everyday manual operations, and what it takes to transition from fragmented workflows to fully integrated, robotic production environments. Stone also discusses the importance of preserving biological integrity during automation, the role of digital data capture in improving consistency and regulatory confidence, and more.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(129)

Accelerating Biopharma Manufacturing Through Integrated Automation

Accelerating Biopharma Manufacturing Through Integrated Automation

Biopharmaceutical manufacturers are facing mounting pressure to scale production faster while maintaining quality and operational reliability due to the ever-expanding pipeline of therapies. Meanwhile...

30 Kesä 21min

The Future of Global Biopharma Manufacturing Networks

The Future of Global Biopharma Manufacturing Networks

Amid ongoing geopolitical uncertainty, regional manufacturing initiatives, and evolving supply chain risks reshaping the pharmaceutical industry, manufacturers are rethinking how biologics are produce...

23 Kesä 12min

Building Flexibility into Biopharma Manufacturing

Building Flexibility into Biopharma Manufacturing

As biopharma pipelines become more complex and market conditions continue to evolve, manufacturers are rethinking how they scale capacity, deploy capital, and build supply chains. The industry’s focus...

16 Kesä 19min

How Biocatalysis Is Changing Pharma Manufacturing

How Biocatalysis Is Changing Pharma Manufacturing

Interest in macrocyclic peptides (MCPs) continues to grow, which means manufacturers are facing mounting pressure to develop production methods capable of supporting commercial-scale demand of these m...

9 Kesä 19min

How Peptide Development Complexity Is Reshaping CDMO Partnerships: Part Two

How Peptide Development Complexity Is Reshaping CDMO Partnerships: Part Two

As peptide therapeutics become larger, more complex, and increasingly purity-sensitive, manufacturers are confronting a new layer of execution challenges. Long-chain peptides introduce compounding sca...

2 Kesä 20min

How Peptide Development Complexity Is Reshaping CDMO Partnerships: Part One

How Peptide Development Complexity Is Reshaping CDMO Partnerships: Part One

Peptide pipelines continue to expand globally, and pharmaceutical companies are increasingly turning to CDMOs earlier in the development lifecycle to help manage growing technical and operational comp...

26 Touko 20min

Solutions Spotlight: Managing Chloramines in Pharmaceutical Water Systems

Solutions Spotlight: Managing Chloramines in Pharmaceutical Water Systems

As municipal water utilities increasingly shift from free chlorine to chloramine disinfection strategies, pharmaceutical manufacturers are facing new challenges in maintaining consistent, high-purity ...

22 Touko 17min

Can CDMO-to-CDMO Collaboration Simplify Drug Development?

Can CDMO-to-CDMO Collaboration Simplify Drug Development?

Amid increasing complexity in the drug development landscape, CDMOs are exploring new ways to streamline the path from early-stage formulation through commercial manufacturing. Rather than operating i...

19 Touko 19min

Suosittua kategoriassa Politiikka ja uutiset

uutiscast
aikalisa
ootsa-kuullut-tasta-2
rss-ootsa-kuullut-tasta
rss-podme-livebox
tervo-halme
otetaan-yhdet
politiikan-puskaradio
rss-asiastudio
the-ulkopolitist
rss-raha-talous-ja-politiikka
aihe
rss-vaalirankkurit-podcast
rss-girls-finish-f1rst
rss-mina-ukkola
rss-kaikki-uusiksi
rss-360-podi
rss-fingo-podcast
rss-kuka-mina-olen
rss-ulkopoditiikkaa